Top-News
Sophiris Bio - Reboundkanditat
Beiträge:
99
Zugriffe: 30.606 / Heute: 11
Zugriffe: 30.606 / Heute: 11
|
Werbung
Entdecke die beliebtesten ETFs von Xtrackers
Xtrackers LevDAX Daily Swap UCITS ETF 1C
Perf. 12M: +68,57%
Xtrackers MSCI Pakistan Swap UCITS ETF 1C
Perf. 12M: +47,77%
Xtrackers Spain UCITS ETF 1D
Perf. 12M: +43,65%
Xtrackers MSCI Europe Financials Screened UCITS ETF 1C
Perf. 12M: +43,64%
Xtrackers Spain UCITS ETF 1C
Perf. 12M: +43,51%
Schau mal in Deinen alten OPXA-Thread und was da so los ist an der Nasdaq, war mal Dein Beobachtungsshare in 2013.
Anzeige: US-Analysten adeln Almonty
Einzigartige Rohstoff-Position, globale Nachfrage, geopolitischer Rückenwind
Financial Results
At March 31, 2015, we had cash, cash equivalents and securities available-for-sale of $17.0 million and net working capital of $15.5 million. We expect that our cash, cash equivalents and securities available-for-sale as of March 31, 2015 will be sufficient to fund our operations through the end of April 2016, assuming that we do not initiate any additional clinical development of PRX302 other than our planned Phase 2a proof of concept trial for low to intermediate risk prostate cancer. We will need to find additional capital to fund a second Phase 3 clinical trial of PRX302 for the treatment of the symptoms of BPH and for any future clinical development of PRX302 for the treatment of localized prostate cancer beyond our planned Phase 2a proof of concept clinical trial.
The Company reported a net loss of $4.3 million ($0.26 per share) for the three months ended March 31, 2015 compared to a net loss of $8.5 million ($0.52 per share) for the three months ended March 31, 2014.
seekingalpha.com/pr/...reports-first-quarter-financial-results
Und die Produkte sind auch schon relativ weit:
Sophiris Bio (SPHS +25.4%) commences a Phase 2a proof-of-concept study assessing its lead product candidate, PRX302, in patients with low-to-intermediate risk prostate cancer. The single-center open-label trial will enroll ~20 patients.
PRX302 (topsalysin) is a modified recombinant protein engineered to be selectively activated by an enzyme in the prostate. It kills cancer cells within the prostate without damaging surrounding tissue. It is currently in Phase 3 development for the treatment of symptoms of benign prostatic hyperplasia (enlarged prostate).
Share this with a colleague
At March 31, 2015, we had cash, cash equivalents and securities available-for-sale of $17.0 million and net working capital of $15.5 million. We expect that our cash, cash equivalents and securities available-for-sale as of March 31, 2015 will be sufficient to fund our operations through the end of April 2016, assuming that we do not initiate any additional clinical development of PRX302 other than our planned Phase 2a proof of concept trial for low to intermediate risk prostate cancer. We will need to find additional capital to fund a second Phase 3 clinical trial of PRX302 for the treatment of the symptoms of BPH and for any future clinical development of PRX302 for the treatment of localized prostate cancer beyond our planned Phase 2a proof of concept clinical trial.
The Company reported a net loss of $4.3 million ($0.26 per share) for the three months ended March 31, 2015 compared to a net loss of $8.5 million ($0.52 per share) for the three months ended March 31, 2014.
seekingalpha.com/pr/...reports-first-quarter-financial-results
Und die Produkte sind auch schon relativ weit:
Sophiris Bio (SPHS +25.4%) commences a Phase 2a proof-of-concept study assessing its lead product candidate, PRX302, in patients with low-to-intermediate risk prostate cancer. The single-center open-label trial will enroll ~20 patients.
PRX302 (topsalysin) is a modified recombinant protein engineered to be selectively activated by an enzyme in the prostate. It kills cancer cells within the prostate without damaging surrounding tissue. It is currently in Phase 3 development for the treatment of symptoms of benign prostatic hyperplasia (enlarged prostate).
Share this with a colleague
sollen anscheinend Ende nächsten Monats kommen...
jetzt auch mal aufm schirm
Gelöschter Beitrag.
Einblenden
»
#15
Gelöschter Beitrag.
Einblenden
»
#16
Die News kam 14:22 Uhr im Nasdaq-Channel! Les nach. Also du warst später. Soviel dazu.
warum ist die aktie gestern so stark gelaufen ??
wollte news übersetzen,blicke aber nicht durch,
kurze erklärung wäre hilfreich.
vielen dank
wollte news übersetzen,blicke aber nicht durch,
kurze erklärung wäre hilfreich.
vielen dank
da schaust mal wieder ins Depot und siehst hier glatt nen Verdoppler! Geil :)
The company mentioned that PRX302 had significantly improved symptoms in men suffering from an enlarged prostate. It did not cause any serious health concerns in any tested patient. Furthermore, it stated that the treatment would be a blockbuster, with potential to garner meaningful annual sales of more than $1 billion.
vorgestern 180% plus und gestern dachte ich
das die shorties gewinnen da sie den kurs auf 2,45$ drückten,
cirka 14% minus
dann drehte der kurs und ging ins plus 3,20$ 10,34%
daher denke ich das es heute weiter hoch geht.
das die shorties gewinnen da sie den kurs auf 2,45$ drückten,
cirka 14% minus
dann drehte der kurs und ging ins plus 3,20$ 10,34%
daher denke ich das es heute weiter hoch geht.
16,6 Mio - freefloat wie hoch ?
Danke KH
Danke KH
Es gibt keine neuen Beiträge.
Ich:
|
